Stockscreener 앱 받기
42.49
1.58%
-0.68
시간 외 거래:
42.49
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
Zenas BioPharma : Corporate Presentation - marketscreener.com
Is Zenas BioPharma Inc. stock attractive after correctionFibonacci Extensions & Target Triple-Digit Stock Opportunities - Bollywood Helpline
Analysts' Revenue Estimates For Zenas BioPharma, Inc. (NASDAQ:ZBIO) Are Surging Higher - simplywall.st
Zenas BioPharma (NASDAQ:ZBIO) Hits New 52-Week HighWhat's Next? - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Trading 8.9% HigherShould You Buy? - MarketBeat
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next - ts2.tech
Zenas Biopharma stock reaches all-time high of 41.67 USD - Investing.com
Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says - marketscreener.com
Wedbush Reiterates Outperform Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to NASDAQ Biotechnology Index - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2025-12-21 | Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation | NDAQ:ZBIO | Press Release - Stockhouse
How interest rate cuts could boost Zenas BioPharma Inc. stockRecession Risk & Weekly Hot Stock Watchlists - ulpravda.ru
Zenas BioPharma approves 2026 inducement plan - MSN
Can Zenas BioPharma Inc. stock reach $100 price target2025 Risk Factors & Short-Term High Return Ideas - Улправда
Why Zenas BioPharma Inc. stock remains on buy listsJuly 2025 Technicals & Stepwise Swing Trade Plans - Улправда
Winners Losers: What sentiment indicators say about Zenas BioPharma Inc. stock2025 Big Picture & Daily Entry Point Trade Alerts - Улправда
Growth Value: How interest rate cuts could boost Zenas BioPharma Inc. stockShare Buyback & Weekly High Return Stock Forecasts - Улправда
Zenas Biopharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Insider Trends: How interest rate cuts could boost Zenas BioPharma Inc. stock - Улправда
Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Is Zenas BioPharma Inc. stock resilient to inflationJuly 2025 Retail & Step-by-Step Trade Execution Guides - DonanımHaber
What insider trading reveals about Zenas BioPharma Inc. stockJuly 2025 Chart Watch & Low Risk Entry Point Guides - DonanımHaber
New Highs: How interest rate cuts could boost Zenas BioPharma Inc. stockTrade Risk Summary & Risk Controlled Stock Alerts - Улправда
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
Earnings Report: Is Zenas BioPharma Inc stock a bargain at current levelsJuly 2025 Earnings & Free Community Supported Trade Ideas - moha.gov.vn
Orelabrutinib’s SLE Phase 2b Success Could Be A Game Changer For Zenas BioPharma (ZBIO) - Sahm
H.C. Wainwright reiterates Buy rating on Zenas Biopharma stock amid competitor setback - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Trading 6.7% HigherTime to Buy? - MarketBeat
Zenas BioPharma Shares Surge Amid Promising Drug Trials - TipRanks
Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential - TipRanks
Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside - TipRanks
Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod - Indian Pharma Post
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Zenas BioPharma (ZBIO): Reassessing Valuation After Orelabrutinib’s Phase 2b Lupus Success and China Phase 3 Green Light - Yahoo Finance
Zenas BioPharma (ZBIO): Reassessing a Rich Valuation After Positive Orelabrutinib Lupus Trial Milestones - Sahm
Zenas BioPharma Approves 2026 Inducement Plan - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 9.9%Should You Sell? - MarketBeat
ZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How - GuruFocus
InnoCare Pharma achieves primary endpoint in Phase 2b study of orelabrutinib - TipRanks
Innocare Pharma announces achievement of primary endpoint in phase 2b study of orelabrutinib - marketscreener.com
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus - The Manila Times
Zenas Prepares For INDIGO Phase 3 Readout—Reinstating Buy Rating (ZBIO) - Seeking Alpha
Zenas BioPharma Says Partner InnoCare's Phase 2b Orelabrutinib Study in Systemic Lupus Erythematosus Meets Primary Endpoint - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
IgG4-related Disease Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht - The Globe and Mail
Is Zenas BioPharma’s (ZBIO) Royalty Deal Quietly Rewriting Its Late-Stage Risk Profile? - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Federated Hermes Inc. Boosts Stake in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Zenas Biopharma stock hits all-time high at 41.37 USD By Investing.com - Investing.com Canada
Zenas Biopharma stock hits all-time high at 41.37 USD - Investing.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - ACCESS Newswire
Would You Still Hold Zenas BioPharma Stock If It Fell 30%? - Trefis
Taking Stock of Zenas BioPharma (ZBIO) Valuation After Royalty Pharma Financing Boost - Sahm
2025-12-04 | Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation | NDAQ:ZBIO | Press Release - Stockhouse
Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation - Insider Monkey
Is Zenas BioPharma Inc. stock trading near support levelsQuarterly Trade Report & Low Risk Entry Point Guides - Newser
Can Zenas BioPharma Stock Hold Up When Markets Turn? - Trefis
Did You Lose Money on Zenas BioPharma, Inc. (ZBIO)? Levi & Korsinsky Urges Investors to Act Before June 16, 2025 - The National Law Review
0.08%
0.21%
자본화:
|
볼륨(24시간):